Advanced training of pediatric providers does not ensure adequate delivery of chest compressions, according to a study in the June issue of Resuscitation.

MitraClip treatment can be performed safely in high-risk patients and results in sustained symptomatic improvement, according to the results of the EVEREST II trial presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd annual scientific sessions in San Diego

Between 2009 and 2010, the number of physicians willing to see pharmaceutical representatives slumped almost 20 percent. Researchers say a more systematic approach to the pharma selling models rather than use of the standard one-size-fits-all approach would help improve efficiency, according to the 2010 AccessMonitor report, conducted by ZS Associates.

For uncontrolled patients on monotherapy who later switched to a fixed combination dose of amlodupine and olmesartan medoxomil (AML/OM), 75.8 percent of hypertensive patients achieved systolic blood pressure (BP) goals of less than 140 mm Hg, according to a poster presentation at the American Society of Hypertension (ASH) May 1-4 in New York City.

Nearly two years after the heparin conundrum where the FDA linked 85 deaths and over 785 severe allergic reactions to tainted lots of the drug manufactured by Baxter International, policymakers have revealed missteps in the unresolved investigation.

The Sorin Group has entered into a distribution agreement with CardioMedical to distribute the Cardio Vision minimally invasive heart valve surgery (MIS) product portfolio of cardiac surgery devices.

Zoll Medical, a manufacturer of resuscitation devices and software, has posted positive incomes and revenues for the second quarter of 2010, which ended March 31.

Merck has made appointments to three top leadership positions including CEO, president and president of global human health positions.